Overview

• GPs in England can now prescribe tirzepatide (Mounjaro) for patients with a BMI over 40 and at least four obesity-related conditions under strict NHS criteria
• The MHRA has recorded nearly 300 cases of acute and chronic pancreatitis and ten deaths among GLP-1 users and is recruiting patients for a Yellow Card genetic biobank study
• Medical experts stress that GLP-1 therapies control appetite but do not address underlying causes of weight gain and caution that weight often returns when treatment stops without ongoing lifestyle support
• Reports from digital clinics like Zava suggest up to 20% of Mounjaro users hit weight-loss plateaus due to improper dosing, diet, activity or other health factors
• An early Phase I trial of Atrogi AB’s experimental oral compound showed weight and blood sugar improvements without the gastrointestinal side effects typical of injectable GLP-1 drugs